Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Samuel Crook"'
Autor:
Kathy F. K. Cheung, Jean-Yves Chiva, Satish Dayal, Darren Stead, Carly L. Nichols, Rob Webster, Lee R. Roberts, David Stonehouse, Felice Daverio, Iain Gardner, Andrew Pike, Michael Paradowski, David C. Blakemore, Gilles H. Goetz, Lesa Watson, Chris Pickford, Jared B.J. Milbank, Ye Che, Robert Wybrow, Florian Wakenhut, Keith Statham, Caroline Smith-Burchnell, Samuel Crook, Fiona M. Adam, David C. Pryde, David Leese, Mike Westby, Duncan Hay, Stephen M. Shaw, Tram T. Tran
Publikováno v:
ChemMedChem. 9:1378-1386
Nonstructural protein 5A (NS5A) represents a novel target for the treatment of hepatitis C virus (HCV). Daclatasvir, recently reported by Bristol-Myers-Squibb, is a potent NS5A inhibitor currently under investigation in phase 3 clinical trials. While
Autor:
Florian Wakenhut, Thien Duc Tran, Chris Pickford, Stephen Shaw, Mike Westby, Caroline Smith-Burchnell, Lesa Watson, Michael Paradowski, Jared Milbank, David Stonehouse, Kathy Cheung, Robert Wybrow, Felice Daverio, Samuel Crook, Keith Statham, David Leese, Darren Stead, Fiona Adam, Duncan Hay, Lee R. Roberts, Jean-Yves Chiva, Carly Nichols, David C. Blakemore, Gilles H. Goetz, Ye Che, Iain Gardner, Satish Dayal, Andrew Pike, Rob Webster, David C. Pryde
Publikováno v:
ChemMedChem. 9(7)
In ongoing studies towards novel hepatitis C virus (HCV) therapeutics, inhibitors of nonstructural protein 5A (NS5A) were evaluated. Specifically, starting from previously reported lead compounds, peripheral substitution patterns of a series of biary